ARTICLE | Company News
BioMarin, La Jolla Pharmaceutical deal
April 6, 2009 7:00 AM UTC
BioMarin did not exercise an option to license worldwide, co-exclusive rights to develop and commercialize La Jolla's Riquent abetimus (LJP 394), excluding the Asia-Pacific region. BioMarin said it ma...